All | Absence of thrombosis | Presence of thrombosis | |
Patients (n) | 149 | 133 | 16 |
Age | 48.3±1.2 | 48.4±1.3 | 47.5±3.3 |
Gender (% female) | 85.9 | 84.2 | 100.0 |
BMI (kg/m2) | 27.5±0.6 | 27.8±0.6 | 24.8±0.9 |
Cholesterol (mg/dL) | 172±3 | 174±3 | 159±6 |
Hypertension (%) | 51.7 | 51.1 | 56.2 |
Diabetes (%) | 6.0 | 6.0 | 6.2 |
Ethnicities | |||
Caucasians (%) | 55.7 | 59.4 | 25.0* |
African–Americans (%) | 34.2 | 32.3 | 50.0 |
Asians (%) | 4.0 | 3.0 | 12.5 |
Others (%) | 6.0 | 5.3 | 12.5 |
PGA (0–3 cm) | 0.7±0.1 | 0.6±0.2 | 0.7±0.2 |
Clinical SELENA-SLEDAI | 1.3±0.2 | 1.2±0.2 | 1.8±0.5 |
Active disease status ≥4 points (%) | 18.2 | 16.7 | 31.2 |
Treatment information | |||
Prednisone (%) | 32.2 | 29.3 | 56.3* |
Hydroxychloroquine (%) | 87.2 | 86.5 | 93.8 |
Azathioprine (%) | 8.1 | 7.5 | 12.5 |
Mycophenolate (%) | 22.8 | 24.0 | 12.5 |
Results are expressed as per cent and average (SEM) as appropriate. Significance (p<0.05) is indicated.
*P<0.05.
BMI, body mass index; PGA, Physician Global Assessment; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index.